Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
NCT00657501
Completed
This study is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of LibiGel 300mcg in the treatment of HSDD in surgically menopausal women.
Gender:
FEMALE
Ages:
Between 30 years and 65 years
Trial Updated:
01/04/2013
Locations: BioSante Site #146, Mobile, Alabama +68 locations
Conditions: Hypoactive Sexual Desire Disorder
Register for Updates
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
NCT01235754
Completed
The objective of this study is to evaluate the persistence of benefit of LibiGel (testosterone gel) 300 mcg/day compared to placebo gel in a 12 week post-treatment period of Hypoactive Sexual Desire Disorder (HSDD) in surgically menopausal women.
Gender:
FEMALE
Ages:
Between 30 years and 66 years
Trial Updated:
01/04/2013
Locations: BioSante Site #095, Hoover, Alabama +101 locations
Conditions: Hypoactive Sexual Desire Disorder
Register for Updates
Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
NCT01323140
Completed
Watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
11/30/2012
Locations: Watson Investigational Site, Ft. Meyers, Florida +1 locations
Conditions: Hypogonadism
Register for Updates
Effect of Testosterone Replacement on Insulin Resistance
NCT00487734
Completed
This study aims to determine whether testosterone replacement improves insulin sensitivity in non-obese men with low testosterone and the metabolic syndrome. The metabolic syndrome includes three of the following five conditions, 1) an elevated blood pressure (greater than 130/85), 2) a triglyceride level greater than 150 mg/dl, 3) an HDL-cholesterol less than 40 mg/dl, 4) glucose levels greater than 100 mg/dl, and 5) a waist measurement greater than 40 inches.
Gender:
MALE
Ages:
Between 20 years and 65 years
Trial Updated:
10/22/2012
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, Virginia
Conditions: Metabolic Syndrome, Hypogonadism
Register for Updates
Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance
NCT01408498
Completed
The study aims to establish a clear causal link between testosterone and threat perception and behavioral responses to threat. Namely, the study focuses whether high levels of testosterone will cause an individual to exhibit increased physiological responses to threat (e.g., increased blood pressure, heart rate, and endocrine responses) and a decreased behavioral response (e.g., ignoring the threat, avoiding the threat, and postponing dealing with the threat). The threat in this study is a socia... Read More
Gender:
MALE
Ages:
Between 18 years and 35 years
Trial Updated:
10/12/2012
Locations: Seay Building, Austin, Texas
Conditions: Testosterone's Effects on Threat Perception/Response
Register for Updates
Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men
NCT01104246
Completed
The study will evaluate the pharmacokinetics of testosterone transdermal systems at steady-state in hypogonadal men.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/02/2012
Locations: Watson investigational site, Miramar, Florida +2 locations
Conditions: Hypogonadism
Register for Updates
Cycled Testosterone Replacement Study
NCT00957528
Completed
The purpose of this study is to determine whether testosterone (male hormone) therapy is effective if administered in a cyclic fashion (periodic dosing) compared to continuous dosing in men aged 60 to 85 years. Effectiveness will be determined based on improvements in body composition, muscle metabolism, muscle strength, and bone metabolism.
Gender:
MALE
Ages:
Between 60 years and 85 years
Trial Updated:
09/04/2012
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Hypogonadism
Register for Updates
Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men
NCT00309855
Completed
This study is being done to understand how testosterone, the major male sex hormone, controls the pituitary gland's secretion of growth hormone (GH). GH is an important metabolic hormone, which controls sugar; fat and protein use in the body and maintains muscle strength and bone calcium content. Both testosterone and GH decline in older men. The age-related fall in these hormones probably contributes to relative frailty, reduced quality of life, bone loss, muscle wasting and impaired sexual fun... Read More
Gender:
MALE
Ages:
Between 50 years and 80 years
Trial Updated:
07/27/2012
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Aging
Register for Updates
Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride
NCT00400335
Completed
The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the bioavailability and pharmacokinetics of various doses of testosterone administered with and without dutasteride
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/31/2012
Locations: GSK Investigational Site, Tacoma, Washington
Conditions: Hypogonadism, Hypogonadism, Male
Register for Updates
Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure
NCT00957034
Terminated
Heart failure (HF) is a complex condition resulting from structural or functional heart diseases that impair the ability of the heart to fill with or pump out blood. The main manifestations of HF are shortness of breath and tiredness which may limit the ability to exercise or perform simple daily physical activities such as walking. Heart disease leading to HF is associated with reduced muscle mass and reduced strength and low blood levels of testosterone; a hormone normally produced by the huma... Read More
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
12/06/2011
Locations: Research Site, Phoenix, Arizona +15 locations
Conditions: Heart Failure
Register for Updates
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
NCT00467259
Completed
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
Gender:
FEMALE
Ages:
Between 45 years and 70 years
Trial Updated:
11/10/2011
Locations: Study Facility, Birmingham, Alabama +114 locations
Conditions: Hypoactive Sexual Desire Disorder
Register for Updates
A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations
NCT00702650
Completed
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product- Testosterone MD-Lotion (cutaneous solution), and this study will evaluate the efficacy via pharmacokinetics of various doses of this product. The study will also assess safety of the product.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/21/2011
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +26 locations
Conditions: Hypogonadism
Register for Updates